CoV vaccinations with the preparation of the U.S. manufacturer Novavax could probably be possible as early as next week. The Ministry of Health announced that the protein-based vaccine would be available from the coming calendar week.
However, “An exact delivery date has not yet been communicated by the manufacturer.” Currently, more than 31,300 Austrians have signed up to be vaccinated with Novavax, according to a roundup in the provinces.
Austria has ordered 750,000 doses of Novavax for the first quarter of 2022. The aim is to target, in particular, those people who have previously refused vaccination. Novavax’s product is the fifth CoV vaccine approved in the EU.
Two doses are injected about three weeks apart. It is a protein vaccine – so it is based on a different technology than previously available preparations. Its effectiveness in protecting against symptomatic infections has been reported by the EU Medicines Agency (EMA) to be around 90 percent.
- source: orf.at/picture: pixabay.com
This post has already been read 56 times!